comparemela.com

Latest Breaking News On - Aad 2024 - Page 1 : comparemela.com

Building a Psoriasis Knockout Regimen Around Risankizumab, with Andrew Blauvelt, MD, MBA

Blauvelt discusses the future research of higher-dose risankizumab for patients with psoriasis and why it may be "disruptive in the treatment space."

United statesSan diegoAndrew blauveltAmerican academy of dermatologyOregon medical research centerAmerican academyAad 2024Sandy blauvelt

Rizankizumab and the KNOCKOUT Study, with Andrew Blauvelt, MD, MBA

Blauvelt discusses the impetus for his phase 2 trial looking at the ability to mitigate pivotal psoriasis memory T cells with risankizumab.

San diegoUnited statesAndrew blauveltAmerican academy of dermatologyOregon medical research centerAmerican academyPsoriasis area severity indexAad 2024Sandy blauvelt

vimarsana © 2020. All Rights Reserved.